abstract |
The invention relates to an antibody that binds to BDCA2. Also described are a pharmaceutical composition for treating systemic lupus erythematosus (SLE), comprising said antibody, and variants thereof. In addition, methods of using and preparing said antibody are described, as well as a nucleic acid encoding an antibody, an expression vector and a host cell. |